Biosci Rep:金银花提取物能够减轻卵清蛋白诱导的过敏性鼻炎

2019-08-01 AlexYang MedSci原创

金银花具有抗病毒、抗氧化和抗炎症的特性。过敏性鼻炎(AR)是免疫球蛋白E(lgE)调控的炎症反应。最近,有研究人员调查了是否金银花提取物(HE)对AR具有治疗作用。研究发现,在AR模型中,HE不仅能够减少挠鼻和打喷嚏的次数,同时也能够减少AR诱导的鼻粘膜损伤。更多的是,HE能够降低血清lgE和组织胺的水平,抑制IL-4和IL-17水平,但能够增加鼻腔灌洗液中IL-2和IFN-γ水平。他们的结果同样

金银花具有抗病毒、抗氧化和抗炎症的特性。过敏性鼻炎(AR)是免疫球蛋白E(lgE)调控的炎症反应。最近,有研究人员调查了是否金银花提取物(HE)对AR具有治疗作用。

研究发现,在AR模型中,HE不仅能够减少挠鼻和打喷嚏的次数,同时也能够减少AR诱导的鼻粘膜损伤。更多的是,HE能够降低血清lgE和组织胺的水平,抑制IL-4和IL-17水平,但能够增加鼻腔灌洗液中IL-2和IFN-γ水平。他们的结果同样表明了HE能够增加forkhead box P3 (Foxp3)和T-box转录因子(T-bet)在AR诱导的鼻粘膜组织中的蛋白水平,而抑制信号转导和激活子STAT3和GATA结合蛋白3(GATA-3)的蛋白水平。通过调节AR诱导的炎症反应和先天免疫响应,HE同样能够减轻OVA诱导的AR。

最后,研究人员指出,HE能够作为治疗AR的可能药物。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1918793, encodeId=4f571918e93fb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 30 10:09:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047139, encodeId=23b8204e1398c, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Dec 14 10:09:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650270, encodeId=2cd016502e0fb, content=<a href='/topic/show?id=b5de3690069' target=_blank style='color:#2F92EE;'>#卵清蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36900, encryptionId=b5de3690069, topicName=卵清蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430623995054, createdName=gostraight, createdTime=Wed Mar 04 02:09:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596999, encodeId=5f27159699998, content=<a href='/topic/show?id=7bab96235f5' target=_blank style='color:#2F92EE;'>#金银花#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96235, encryptionId=7bab96235f5, topicName=金银花)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40fa18449129, createdName=marongnuan, createdTime=Sat Aug 03 04:09:00 CST 2019, time=2019-08-03, status=1, ipAttribution=)]
    2019-08-30 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1918793, encodeId=4f571918e93fb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 30 10:09:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047139, encodeId=23b8204e1398c, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Dec 14 10:09:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650270, encodeId=2cd016502e0fb, content=<a href='/topic/show?id=b5de3690069' target=_blank style='color:#2F92EE;'>#卵清蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36900, encryptionId=b5de3690069, topicName=卵清蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430623995054, createdName=gostraight, createdTime=Wed Mar 04 02:09:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596999, encodeId=5f27159699998, content=<a href='/topic/show?id=7bab96235f5' target=_blank style='color:#2F92EE;'>#金银花#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96235, encryptionId=7bab96235f5, topicName=金银花)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40fa18449129, createdName=marongnuan, createdTime=Sat Aug 03 04:09:00 CST 2019, time=2019-08-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1918793, encodeId=4f571918e93fb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 30 10:09:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047139, encodeId=23b8204e1398c, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Dec 14 10:09:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650270, encodeId=2cd016502e0fb, content=<a href='/topic/show?id=b5de3690069' target=_blank style='color:#2F92EE;'>#卵清蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36900, encryptionId=b5de3690069, topicName=卵清蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430623995054, createdName=gostraight, createdTime=Wed Mar 04 02:09:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596999, encodeId=5f27159699998, content=<a href='/topic/show?id=7bab96235f5' target=_blank style='color:#2F92EE;'>#金银花#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96235, encryptionId=7bab96235f5, topicName=金银花)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40fa18449129, createdName=marongnuan, createdTime=Sat Aug 03 04:09:00 CST 2019, time=2019-08-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1918793, encodeId=4f571918e93fb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 30 10:09:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047139, encodeId=23b8204e1398c, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Dec 14 10:09:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650270, encodeId=2cd016502e0fb, content=<a href='/topic/show?id=b5de3690069' target=_blank style='color:#2F92EE;'>#卵清蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36900, encryptionId=b5de3690069, topicName=卵清蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430623995054, createdName=gostraight, createdTime=Wed Mar 04 02:09:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596999, encodeId=5f27159699998, content=<a href='/topic/show?id=7bab96235f5' target=_blank style='color:#2F92EE;'>#金银花#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96235, encryptionId=7bab96235f5, topicName=金银花)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40fa18449129, createdName=marongnuan, createdTime=Sat Aug 03 04:09:00 CST 2019, time=2019-08-03, status=1, ipAttribution=)]

相关资讯

Allergy Asthma Proc:常年性变应性鼻炎患者奥洛他定-莫米松组合鼻喷雾的长期安全性和效果研究

最近,有研究人员调查了GSP301鼻喷雾的安全性和效果,具体是详细调查了GSP301在常年性变应性鼻炎患者(PAR)中的长期(52周)安全性和效果情况。研究是一个随机、双盲和平行的研究,包括了601名PAR患者(年龄不小于12岁),并按章4:1:1的比例随机分配到1天2次GSP301(奥洛帕他定665毫克和莫米松25微克[pH 3.7])或者2种GSP301药物处方(安慰剂pH3.7或者7.0)。

盘点:鼻炎新近进展盘点

【1】Am J Rhinol Allergy:儿科慢性鼻窦炎患者的特应性和生活质量研究 https://www.ncbi.nlm.nih.gov/pubmed/31161768特应性参与了慢性鼻窦炎(CRS)的发展,过敏性鼻炎(AR)也是儿科和成年CRS患者常见的共存疾病。而AR对CRS的贡献情况仍旧不清楚。最近,有研究人员确定了CRS儿科患者的特应性情况以及特应性状态对疾病严重度和生活质量的

盘点:鼻炎与治疗盘点

【1】BMC Cancer:减容调强放射治疗在鼻咽癌治疗中的优势分析 https://www.ncbi.nlm.nih.gov/pubmed/31176358鼻咽癌(NPC)治疗中,强度调节放射治疗(IMRT)中的临床靶标体积(CTV)定义尚未明确。最近,有研究人员评估了减容CTV IMRT治疗在鼻咽癌中的治疗情况。研究人员回顾了2002年到2013年IMRT治疗的293名非转移NPC患者数据

Respir Med:抑郁与哮喘和鼻炎症状的恶化有关

尽管许多研究强调了哮喘/鼻炎与抑郁之间的联系。但是仍旧不清楚到底这些疾病的哪个特性与抑郁的风险相关。最近,有研究人员探索了抑郁与哮喘或者鼻炎之间的关系。研究包括了2227名参与者(年龄在21-86岁,女性占比50%)。研究人员对他们进行了标准化的访谈、皮刺测试和肺功能测试,并分成哮喘组(n=528)、鼻炎组(n=972)和对照组(n=727)。研究发现,在哮喘组、鼻炎组和对照组中,抑郁的患病率分别

Int Arch Allergy Immunol:舌下螨免疫疗法在单敏和多敏过敏性鼻炎儿童中治疗长期效果研究

一些国外的研究表明了舌下免疫治疗(SLIT)具有长期的效果,但是关于SLIT在中国的长期效果数据仍旧缺乏。最近,有研究人员前瞻性的评估了2年SLIT粉尘螨滴剂治疗在单敏和多敏过敏性鼻炎(AR)儿童中的长期效果情况。研究包括了80名HDM敏感的AR儿童(年龄4-12岁)。其中有40名儿童同时在单敏(只对HDM敏感)和多敏分组中。研究跟踪调查的时间为7年。研究人员指出,共有31(77.5%)名单敏儿童

Allergy Asthma Proc:益生菌补充疗法在治疗哮喘、过敏性鼻炎和湿疹中的效果研究

益生菌补充疗法来改善过敏性疾病,包括儿童哮喘,已经在非常多的随机对照研究中有所探索。然而,关于益生菌补充疗法在怀孕和婴儿时期对哮喘和过敏性鼻炎发病率的影响结果还存在争议。最近,有研究人员系统性的探索了益生菌补充疗法对哮喘、过敏性鼻炎和湿疹发生和发展的影响。研究包括了17个随机对照研究,共包括了5264名儿童。研究发现,益生菌补充治疗后发展为哮喘的风险与对照相比没有显著的减少(风险比[RR] 0.8